COVID-19医薬品関連APIの世界市場レポート 2025年

COVID-19医薬品関連API市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.2％で90億8,000万米ドルに成長します。予測期間の成長は、新しいCOVID-19薬剤モダリティの開発、COVID-19薬剤の臨床試験の増加、COVID-19ワクチンの需要増加、新興亜種、ワクチン接種キャンペーン、パンデミック対策に起因すると考えられます。予測期間の主な動向には、カスタマイズされたAPI生産、APIソースの多様化、高度な製造技術、デジタル化とデータ分析、持続可能性とグリーンケミストリーが含まれます。

抗レトロウイルス薬、抗マラリア薬、呼吸器官用薬などの主要医薬品の需要急増により、COVID-19医薬品の製造に不可欠な原薬（API）のニーズが高まっています。レムデシビルとファビピラビルは、COVID-19治療に使用される著名な抗ウイルス薬のひとつです。Remdesivirは米国と日本で緊急承認され、Airsupraは気管支収縮と喘息の予防薬としてFDAに承認されました。COVID-19の呼吸器への影響により、気管支拡張薬の需要は大幅に拡大しました。その結果、抗ウイルス薬、抗マラリア薬、気管支拡張薬に対するこうした需要の増加が、COVID-19医薬品関連API市場を牽引すると予想されます。

ヘルスケアにおける研究開発を目的とした政府の取り組みが、今後のCOVID-19薬剤関連API市場の成長を促進すると予想されます。こうした取り組みには、特定の課題に取り組み、特定の目標を達成し、社会に前向きな変化をもたらすために、地方、地域、国、国際などさまざまなレベルの政府当局が実施する具体的な行動、プログラム、政策、プロジェクトが含まれます。このようなイニシアチブは、COVID-19医薬品関連APIの開発、生産、流通を支援する環境を育成する上で極めて重要です。例えば、2022年3月のGov.UKの報告によると、保健社会福祉省はビジネス・エネルギー・産業戦略省とともに、新しいプライバシー保護プラットフォームや臨床研究サービスを活用し、診断や治療に焦点を当てたNHS主導の健康研究を支援するため、最大2億5,970万米ドル（2億英ポンド）を拠出することを約束しました。このように、ヘルスケア研究開発における政府の取り組みは、COVID-19薬剤関連API市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界COVID-19医薬品関連API PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のCOVID-19医薬品関連API市場：成長率分析
• 世界のCOVID-19医薬品関連API市場の実績：規模と成長, 2019-2024
• 世界のCOVID-19医薬品関連API市場の予測：規模と成長, 2024-2029, 2034F
• 世界COVID-19医薬品関連API総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のCOVID-19医薬品関連API市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗マラリア薬
• 気管支拡張薬
• 抗生物質
• 抗ウイルス薬
• その他の薬物クラス
• 世界のCOVID-19医薬品関連API市場合成タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 合成
• バイオテクノロジー
• 世界のCOVID-19医薬品関連API市場ビジネスモード別、実績と予測, 2019-2024, 2024-2029F, 2034F
• キャプティブAPI
• マーチャントAPI
• 世界のCOVID-19医薬品関連API市場抗マラリア薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒドロキシクロロキン
• クロロキン
• 世界のCOVID-19医薬品関連API市場気管支拡張薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベータ作動薬
• 抗コリン薬
• 世界のCOVID-19医薬品関連API市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• マクロライド
• テトラサイクリン
• 世界のCOVID-19医薬品関連API市場抗ウイルス薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レムデシビル
• ファビピラビル
• ロピナビルまたはリトナビル
• 世界のCOVID-19医薬品関連API市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫調節薬

第7章 地域別・国別分析

• 世界のCOVID-19医薬品関連API市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のCOVID-19医薬品関連API市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• COVID-19医薬品関連API市場：競合情勢
• COVID-19医薬品関連API市場：企業プロファイル
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Lianyungang Guike Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Alembic Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Wockhardt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz Srl Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Lupin Limited
• Aurobindo Pharma Ltd.
• Shanghai Shyndec Pharmaceutical Co. Ltd.
• Zhejiang Yatai Pharmaceutical Co. Ltd.
• Zhejiang Guobang Pharmaceutical Co. Ltd.
• Cipla Limited
• Shandong Boyuan Pharmaceutical Co. Ltd.
• Aspiro Pharma Ltd.
• Qilu Antibiotics Pharmaceutical Co. Ltd.
• Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd.
• Zhejiang Cheng Yi Pharmaceutical
• Star Lake Bioscience Co. Inc.
• Hetero Labs Ltd.
• Geno Pharmaceuticals Ltd.
• Mylan Laboratories Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• COVID-19医薬品関連API市場2029：新たな機会を提供する国
• COVID-19医薬品関連API市場2029：新たな機会を提供するセグメント
• COVID-19医薬品関連API市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

COVID-19 drug-associated APIs constitute the active pharmaceutical ingredients utilized in the formulation of medications targeting the virus. These APIs serve as the fundamental chemical components responsible for the pharmacological effects within the human body.

The primary classes of drugs categorized as COVID-19 drug-associated APIs encompass antimalarials, bronchodilators, antibiotics, antivirals, and other related categories. Antimalarial drugs, specifically, are antiparasitic agents used to treat or prevent malaria, commonly sourced from organic origins. These drugs exist in various forms, including generic and branded versions, and are involved in different business models such as captive API (produced for internal use) and merchant API (commercially available for external sales).

The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, COVID-19 drug-associated APIs market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The COVID-19 drug associated apis market size has grown strongly in recent years. It will grow from $6.75 billion in 2024 to $7.14 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to the rising prevalence of COVID-19, increasing awareness of COVID-19 treatment options, expanding access to COVID-19 drugs, growing demand for COVID-19 drugs for prophylaxis, government initiatives, and supply chain resilience.

The COVID-19 drug associated apis market size is expected to see strong growth in the next few years. It will grow to $9.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the development of new COVID-19 drug modalities, increasing clinical trials for COVID-19 drugs, rising demand for COVID-19 vaccines, emerging variants, vaccination campaigns, and pandemic preparedness. Major trends in the forecast period include customized API production, diversification of API sources, advanced manufacturing technologies, digitalization and data analytics, sustainability and green chemistry.

The surging demand for key pharmaceuticals like antiretrovirals, antimalarials, and respiratory drugs has led to increased need for active pharmaceutical ingredients (APIs) crucial in manufacturing COVID-19 medications. Remdesivir and Favipiravir are among the prominent antiviral drugs used for COVID-19 treatment. Remdesivir gained emergency approval in the USA and Japan, while the FDA approved Airsupra for bronchoconstriction and asthma prevention. The demand for bronchodilators escalated significantly due to COVID-19's respiratory impact. Consequently, this increased demand for antivirals, antimalarials, and bronchodilators is expected to drive the market for COVID-19 drug-associated APIs.

Government initiatives aimed at research and development in healthcare are expected to drive the growth of the COVID-19 drug-associated API market in the future. These initiatives encompass specific actions, programs, policies, or projects implemented by government authorities at various levels-local, regional, national, or international-to tackle particular challenges, achieve specific objectives, or bring about positive societal changes. Such initiatives are crucial in fostering an environment that supports the development, production, and distribution of COVID-19 drug-associated APIs. For instance, a report from Gov.UK in March 2022 indicated that the Department of Health and Social Care, along with the Department for Business, Energy and Industrial Strategy, has pledged up to $259.70 million (£200 million) to support NHS-led health research focused on diagnostics and treatment, utilizing new privacy-preserving platforms and clinical research services. Thus, government initiatives in healthcare research and development are propelling the growth of the COVID-19 drug-associated API market.

Major pharmaceutical players are strategizing capacity expansions to meet the escalating demand for COVID-19 drug-related APIs amid rising global COVID-19 cases. Merck & Co., Inc., in partnership with India's Heavy Water Board, aims to delve into the deuterated raw compound industry, potentially worth $1 billion in the next decade. Merck aims to support sectors like chemicals, pharmaceuticals, and electronics by supplying high-quality compounds. Avigan, currently undergoing clinical trials, is being tested for its effectiveness in treating COVID-19 patients.

Top companies in the COVID-19 drug-associated APIs market are focusing on innovation, such as oral treatments, to gain a competitive advantage. In 2023, Pfizer Inc.'s PAXLOVID, an oral SARS-CoV-2 protease inhibitor approved by the FDA, demonstrated an 89% reduction in hospitalization or death risk compared to a placebo in high-risk, non-hospitalized adults with COVID-19. Designed for early administration, it aims to prevent severe illness and hospitalization, making a significant impact in managing the infection.

In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, completed the acquisition of an undisclosed active pharmaceutical ingredient (API) manufacturing facility from Novartis, a prominent pharmaceutical company based in the US. This strategic acquisition marks an expansion of Sterling's capabilities in API manufacturing. The deal also includes a continued supply arrangement between Sterling and Novartis, ensuring the manufacturing of several APIs utilized in cardiovascular, immunology, and oncology medications. Novartis AG, known for its production of active pharmaceutical ingredients, initiated this transfer as part of their strategic reorganization.

Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.

North America was the largest region in the COVID-19 drug-associated APIs market in 2024. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market share during the forecast period. The regions covered in the COVID-19 drug associated apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the COVID-19 drug associated apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

COVID-19 Drug Associated APIs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on covid-19 drug associated apis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for covid-19 drug associated apis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The covid-19 drug associated apis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antimalarials; Bronchodilators; Antibiotics; Antivirals; Other Drug Class
• 2) By Synthesis Type: Synthetic; Biotech
• 3) By Business Mode: Captive API; Merchant API
• Subsegments:
• 1) By Antimalarials: Hydroxychloroquine; Chloroquine
• 2) By Bronchodilators: Beta-Agonists; Anticholinergics
• 3) By Antibiotics: Macrolides; Tetracyclines
• 4) By Antivirals: Remdesivir; Favipiravir; Lopinavir Or Ritonavir
• 5) By Other Drug Classes: Corticosteroids; Immunomodulators
• Companies Mentioned: Dr. Reddy's Laboratories Ltd.; Lianyungang Guike Pharmaceutical CO. LTD.; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.; Sandoz Srl
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. COVID-19 Drug Associated APIs Market Characteristics

3. COVID-19 Drug Associated APIs Market Trends And Strategies

4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global COVID-19 Drug Associated APIs Growth Analysis And Strategic Analysis Framework

• 5.1. Global COVID-19 Drug Associated APIs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global COVID-19 Drug Associated APIs Market Growth Rate Analysis
• 5.4. Global COVID-19 Drug Associated APIs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global COVID-19 Drug Associated APIs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global COVID-19 Drug Associated APIs Total Addressable Market (TAM)

6. COVID-19 Drug Associated APIs Market Segmentation

• 6.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimalarials
• Bronchodilators
• Antibiotics
• Antivirals
• Other Drug Class
• 6.2. Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic
• Biotech
• 6.3. Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Captive API
• Merchant API
• 6.4. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Antimalarials, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydroxychloroquine
• Chloroquine
• 6.5. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta-Agonists
• Anticholinergics
• 6.6. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macrolides
• Tetracyclines
• 6.7. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Remdesivir
• Favipiravir
• Lopinavir Or Ritonavir
• 6.8. Global COVID-19 Drug Associated APIs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunomodulators

7. COVID-19 Drug Associated APIs Market Regional And Country Analysis

• 7.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific COVID-19 Drug Associated APIs Market

• 8.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China COVID-19 Drug Associated APIs Market

• 9.1. China COVID-19 Drug Associated APIs Market Overview
• 9.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India COVID-19 Drug Associated APIs Market

• 10.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan COVID-19 Drug Associated APIs Market

• 11.1. Japan COVID-19 Drug Associated APIs Market Overview
• 11.2. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia COVID-19 Drug Associated APIs Market

• 12.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia COVID-19 Drug Associated APIs Market

• 13.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea COVID-19 Drug Associated APIs Market

• 14.1. South Korea COVID-19 Drug Associated APIs Market Overview
• 14.2. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe COVID-19 Drug Associated APIs Market

• 15.1. Western Europe COVID-19 Drug Associated APIs Market Overview
• 15.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK COVID-19 Drug Associated APIs Market

• 16.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany COVID-19 Drug Associated APIs Market

• 17.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France COVID-19 Drug Associated APIs Market

• 18.1. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy COVID-19 Drug Associated APIs Market

• 19.1. Italy COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain COVID-19 Drug Associated APIs Market

• 20.1. Spain COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe COVID-19 Drug Associated APIs Market

• 21.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview
• 21.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia COVID-19 Drug Associated APIs Market

• 22.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America COVID-19 Drug Associated APIs Market

• 23.1. North America COVID-19 Drug Associated APIs Market Overview
• 23.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA COVID-19 Drug Associated APIs Market

• 24.1. USA COVID-19 Drug Associated APIs Market Overview
• 24.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada COVID-19 Drug Associated APIs Market

• 25.1. Canada COVID-19 Drug Associated APIs Market Overview
• 25.2. Canada COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America COVID-19 Drug Associated APIs Market

• 26.1. South America COVID-19 Drug Associated APIs Market Overview
• 26.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil COVID-19 Drug Associated APIs Market

• 27.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East COVID-19 Drug Associated APIs Market

• 28.1. Middle East COVID-19 Drug Associated APIs Market Overview
• 28.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa COVID-19 Drug Associated APIs Market

• 29.1. Africa COVID-19 Drug Associated APIs Market Overview
• 29.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

• 30.1. COVID-19 Drug Associated APIs Market Competitive Landscape
• 30.2. COVID-19 Drug Associated APIs Market Company Profiles
  • 30.2.1. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Lianyungang Guike Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Alembic Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Wockhardt Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sandoz Srl Overview, Products and Services, Strategy and Financial Analysis

31. COVID-19 Drug Associated APIs Market Other Major And Innovative Companies

• 31.1. Lupin Limited
• 31.2. Aurobindo Pharma Ltd.
• 31.3. Shanghai Shyndec Pharmaceutical Co. Ltd.
• 31.4. Zhejiang Yatai Pharmaceutical Co. Ltd.
• 31.5. Zhejiang Guobang Pharmaceutical Co. Ltd.
• 31.6. Cipla Limited
• 31.7. Shandong Boyuan Pharmaceutical Co. Ltd.
• 31.8. Aspiro Pharma Ltd.
• 31.9. Qilu Antibiotics Pharmaceutical Co. Ltd.
• 31.10. Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd.
• 31.11. Zhejiang Cheng Yi Pharmaceutical
• 31.12. Star Lake Bioscience Co. Inc.
• 31.13. Hetero Labs Ltd.
• 31.14. Geno Pharmaceuticals Ltd.
• 31.15. Mylan Laboratories Ltd.

32. Global COVID-19 Drug Associated APIs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

34. Recent Developments In The COVID-19 Drug Associated APIs Market

35. COVID-19 Drug Associated APIs Market High Potential Countries, Segments and Strategies

• 35.1 COVID-19 Drug Associated APIs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 COVID-19 Drug Associated APIs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 COVID-19 Drug Associated APIs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer